BioTime’s technology platform in the field of human pluripotent stem cells results in a wide array of potential research and therapeutic products. Our business strategies include the establishment of subsidiaries focused on particular fields of application.

These subsidiaries currently include:

Embryome Sciences, Inc.

BioTime Asia, Limited

Oncocyte, Corp.

ES Cell International Pte Ltd